Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tuomas Mirtti

Showing results (71-80 of 125) with videos related to

Pageof 13
Sort By:
The American Journal of Pathology|May 17, 2008
Stat3 promotes metastatic progression of prostate cancerJunaid Abdulghani, Lei Gu, Ayush Dagvadorj, et al.
International Journal of Cancer|February 19, 2016
Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomyLan Yu, Mervi Toriseva, Miikka Tuomala, et al.
Endocrinology|April 7, 2007
Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathwayAyush Dagvadorj, Sean Collins, Jean-Baptiste Jomain, et al.
Molecular Cancer Therapeutics|March 1, 2014
Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formationLei Gu, Pooja Talati, Paraskevi Vogiatzi, et al.
International Journal of Cancer|August 21, 2018
Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient-derived cancer cellsKhalid Saeed, Poojitha Ojamies, Teijo Pellinen, et al.
The American Journal of Pathology|February 2, 2011
Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancerPaula Vainio, Santosh Gupta, Kirsi Ketola, et al.
International Journal of Cancer|May 4, 2023
Prognostic impact of kallikrein-related peptidase transcript levels in prostate cancerTimo-Pekka K Lehto, Ruusu-Maaria Kovanen, Susanna Lintula, et al.
Cancer Letters|September 25, 2025
AI-informed computational pathology classifier predicts outcomes across treatment modalities in muscle-invasive urothelial carcinomaKamal Hammouda, Naoto Tokuyama, Germán Corredor, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 5, 2016
Benefit of Adjuvant Chemotherapy and Pelvic Lymph Node Dissection in pT3 and Node Positive Bladder Cancer Patients Treated with Radical CystectomyPeter J Boström, Tuomas Mirtti, Bas van Rhijn, et al.
Cancer Research Communications|July 24, 2023
Immunologic Characterization and T cell Receptor Repertoires of Expanded Tumor-infiltrating Lymphocytes in Patients with Renal Cell CarcinomaMoon Hee Lee, Jason Theodoropoulos, Jani Huuhtanen, et al.
Pageof 13

Showing results (71-80 of 125) with videos related to

Sort By:
Pageof 13
The American Journal of Pathology|May 17, 2008
Stat3 promotes metastatic progression of prostate cancerJunaid Abdulghani, Lei Gu, Ayush Dagvadorj, et al.
International Journal of Cancer|February 19, 2016
Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomyLan Yu, Mervi Toriseva, Miikka Tuomala, et al.
Endocrinology|April 7, 2007
Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathwayAyush Dagvadorj, Sean Collins, Jean-Baptiste Jomain, et al.
Molecular Cancer Therapeutics|March 1, 2014
Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formationLei Gu, Pooja Talati, Paraskevi Vogiatzi, et al.
International Journal of Cancer|August 21, 2018
Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient-derived cancer cellsKhalid Saeed, Poojitha Ojamies, Teijo Pellinen, et al.
The American Journal of Pathology|February 2, 2011
Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancerPaula Vainio, Santosh Gupta, Kirsi Ketola, et al.
International Journal of Cancer|May 4, 2023
Prognostic impact of kallikrein-related peptidase transcript levels in prostate cancerTimo-Pekka K Lehto, Ruusu-Maaria Kovanen, Susanna Lintula, et al.
Cancer Letters|September 25, 2025
AI-informed computational pathology classifier predicts outcomes across treatment modalities in muscle-invasive urothelial carcinomaKamal Hammouda, Naoto Tokuyama, Germán Corredor, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 5, 2016
Benefit of Adjuvant Chemotherapy and Pelvic Lymph Node Dissection in pT3 and Node Positive Bladder Cancer Patients Treated with Radical CystectomyPeter J Boström, Tuomas Mirtti, Bas van Rhijn, et al.
Cancer Research Communications|July 24, 2023
Immunologic Characterization and T cell Receptor Repertoires of Expanded Tumor-infiltrating Lymphocytes in Patients with Renal Cell CarcinomaMoon Hee Lee, Jason Theodoropoulos, Jani Huuhtanen, et al.
Pageof 13